Menu Search
Equities

Merck KGaA

MRKX:GER

Merck KGaA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)138.30
  • Today's Change0.20 / 0.14%
  • Shares traded214.14k
  • 1 Year change-15.31%
  • Beta0.6784
Data delayed at least 15 minutes, as of Nov 21 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy6
Outperform11
Hold2
Sell1
Strong Sell0

Share price forecast in EUR

The 17 analysts offering 12 month price targets for Merck KGaA have a median target of 185.00, with a high estimate of 205.00 and a low estimate of 160.00. The median estimate represents a 33.77% increase from the last price of 138.30.
High48.2%205.00
Med33.8%185.00
Low15.7%160.00

Dividends in EUR

In 2023, Merck KGaA reported a dividend of 2.20 EUR, equaling last years dividend. The 14 analysts covering the company expect dividends of 2.30 EUR for the upcoming fiscal year, an increase of 4.36%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in EUR

On Nov 14, 2024, Merck KGaA reported 3rd quarter 2024 earnings of 2.30 per share. This result was in line with the consensus of the 6 analysts following the company and exceeded last year's 3rd quarter results by 11.11%.
The next earnings announcement is expected on Mar 06, 2025.
Average growth rate+3.02%
Merck KGaA reported annual 2023 earnings of 8.49 per share on Mar 07, 2024.
Average growth rate+12.60%
More ▼

Revenue history & estimates in EUR

MERCK Kommanditgesellschaft auf Aktien had 3rd quarter 2024 revenues of 5.27bn. This missed the 5.33bn consensus estimate of the 6 analysts following the company. This was 0.51% below the prior year's 3rd quarter results.
Average growth rate+0.48%
MERCK Kommanditgesellschaft auf Aktien had revenues for the full year 2023 of 20.99bn. This was 5.57% below the prior year's results.
Average growth rate+7.05%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.